Waldenström macroglobulinaemia

Irene M. Ghobrial, Morie Gertz, Rafael Fonseca

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Waldenström macroglobulinemia (WM) is a lymphoid neoplasm characterised by a monoclonal lymphoplasmacytic expansion accompanied by a serum monoclonal immunoglobulin M (IgM). In some patients, the monoclonal protein will lead to a characteristic hyperviscosity syndrome. Although indolent, WM is incurable and most patients eventually succumb to disease progression. Thus, we need to better understand the natural history and biology of the disease. Recent work has shown that half of patients with WM harbour deletions in the long arm of chromosome 6. Increasing evidence suggests the disease is a defined pathological entity and not purely a clinical syndrome. Current therapeutic modalities include alkylator agents, purine nucleoside analogues, and rituximab. The optimum initial therapeutic strategy is not yet defined, and current clinical trials are addressing the role of combination therapy. In this review, we summarise the current understanding of the pathogenesis, clinical and laboratory features, prognostic factors, and therapeutic options for patients with WM. We also discuss current knowledge of WM and available therapies.

Original languageEnglish (US)
Pages (from-to)679-685
Number of pages7
JournalLancet Oncology
Volume4
Issue number11
DOIs
StatePublished - Nov 2003

Fingerprint

Waldenstrom Macroglobulinemia
Purine Nucleosides
Therapeutics
Chromosomes, Human, Pair 6
Alkylating Agents
Natural History
Immunoglobulin M
Disease Progression
Clinical Trials
Serum
Neoplasms
Proteins

ASJC Scopus subject areas

  • Oncology

Cite this

Waldenström macroglobulinaemia. / Ghobrial, Irene M.; Gertz, Morie; Fonseca, Rafael.

In: Lancet Oncology, Vol. 4, No. 11, 11.2003, p. 679-685.

Research output: Contribution to journalArticle

Ghobrial, Irene M. ; Gertz, Morie ; Fonseca, Rafael. / Waldenström macroglobulinaemia. In: Lancet Oncology. 2003 ; Vol. 4, No. 11. pp. 679-685.
@article{e750e608291d4f01bb59f7ca09e5f02e,
title = "Waldenstr{\"o}m macroglobulinaemia",
abstract = "Waldenstr{\"o}m macroglobulinemia (WM) is a lymphoid neoplasm characterised by a monoclonal lymphoplasmacytic expansion accompanied by a serum monoclonal immunoglobulin M (IgM). In some patients, the monoclonal protein will lead to a characteristic hyperviscosity syndrome. Although indolent, WM is incurable and most patients eventually succumb to disease progression. Thus, we need to better understand the natural history and biology of the disease. Recent work has shown that half of patients with WM harbour deletions in the long arm of chromosome 6. Increasing evidence suggests the disease is a defined pathological entity and not purely a clinical syndrome. Current therapeutic modalities include alkylator agents, purine nucleoside analogues, and rituximab. The optimum initial therapeutic strategy is not yet defined, and current clinical trials are addressing the role of combination therapy. In this review, we summarise the current understanding of the pathogenesis, clinical and laboratory features, prognostic factors, and therapeutic options for patients with WM. We also discuss current knowledge of WM and available therapies.",
author = "Ghobrial, {Irene M.} and Morie Gertz and Rafael Fonseca",
year = "2003",
month = "11",
doi = "10.1016/S1470-2045(03)01246-4",
language = "English (US)",
volume = "4",
pages = "679--685",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "11",

}

TY - JOUR

T1 - Waldenström macroglobulinaemia

AU - Ghobrial, Irene M.

AU - Gertz, Morie

AU - Fonseca, Rafael

PY - 2003/11

Y1 - 2003/11

N2 - Waldenström macroglobulinemia (WM) is a lymphoid neoplasm characterised by a monoclonal lymphoplasmacytic expansion accompanied by a serum monoclonal immunoglobulin M (IgM). In some patients, the monoclonal protein will lead to a characteristic hyperviscosity syndrome. Although indolent, WM is incurable and most patients eventually succumb to disease progression. Thus, we need to better understand the natural history and biology of the disease. Recent work has shown that half of patients with WM harbour deletions in the long arm of chromosome 6. Increasing evidence suggests the disease is a defined pathological entity and not purely a clinical syndrome. Current therapeutic modalities include alkylator agents, purine nucleoside analogues, and rituximab. The optimum initial therapeutic strategy is not yet defined, and current clinical trials are addressing the role of combination therapy. In this review, we summarise the current understanding of the pathogenesis, clinical and laboratory features, prognostic factors, and therapeutic options for patients with WM. We also discuss current knowledge of WM and available therapies.

AB - Waldenström macroglobulinemia (WM) is a lymphoid neoplasm characterised by a monoclonal lymphoplasmacytic expansion accompanied by a serum monoclonal immunoglobulin M (IgM). In some patients, the monoclonal protein will lead to a characteristic hyperviscosity syndrome. Although indolent, WM is incurable and most patients eventually succumb to disease progression. Thus, we need to better understand the natural history and biology of the disease. Recent work has shown that half of patients with WM harbour deletions in the long arm of chromosome 6. Increasing evidence suggests the disease is a defined pathological entity and not purely a clinical syndrome. Current therapeutic modalities include alkylator agents, purine nucleoside analogues, and rituximab. The optimum initial therapeutic strategy is not yet defined, and current clinical trials are addressing the role of combination therapy. In this review, we summarise the current understanding of the pathogenesis, clinical and laboratory features, prognostic factors, and therapeutic options for patients with WM. We also discuss current knowledge of WM and available therapies.

UR - http://www.scopus.com/inward/record.url?scp=0242439419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242439419&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(03)01246-4

DO - 10.1016/S1470-2045(03)01246-4

M3 - Article

C2 - 14602248

AN - SCOPUS:0242439419

VL - 4

SP - 679

EP - 685

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 11

ER -